Related Experiment Video

Updated: May 23, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

New therapeutic targets in soft tissue sarcoma

Elizabeth G Demicco1, Robert G Maki, Dina C Lev

  • 1Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030-4009, USA.

Advances in Anatomic Pathology
|April 14, 2012
PubMed

Insights

Targeted therapy for soft tissue sarcomas is advancing, driven by molecular classification. This review covers current successes, challenges, and future opportunities in developing novel agents for these rare cancers.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Pharmacology

Background:

  • Soft tissue sarcomas (STS) are a heterogeneous group of over 50 mesenchymal malignancies with complex pathogenesis.
  • Advances in molecular classification have identified specific alterations driving STS development.
  • Understanding these molecular drivers is crucial for developing effective treatments.

Purpose of the Study:

  • To review the rationale and progress of targeted therapy in soft tissue sarcomas.
  • To emphasize the role of molecular factors and pathways in translocation-associated and genetically complex STS.
  • To discuss current successes, challenges, and future directions in sarcoma-targeted therapy.

Main Methods:

  • Literature review focusing on molecular alterations, targeted agents, and clinical trial data in soft tissue sarcomas.
  • Analysis of translocation-associated sarcomas and genetically complex tumor subtypes.
  • Evaluation of preclinical and early-phase clinical data for novel therapeutic targets and agents.

Main Results:

  • Molecular classification has enabled the development of targeted agents for specific sarcoma subtypes.
  • Early successes in targeted therapy have been observed, alongside notable challenges and disappointments.
  • Several promising novel therapeutic targets and biological agents are under investigation.

Conclusions:

  • Targeted therapy represents a significant advancement in the management of soft tissue sarcomas.
  • Continued research into molecular mechanisms and novel agents is essential for improving patient outcomes.
  • The field is evolving, with potential for new breakthroughs in the coming years.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...